Owkin

Owkin is pioneering the integration of human and artificial intelligence to deliver better drugs and diagnostics at scale. As the first end-to-end AI biotech, Owkin aims to understand complex biology through cutting-edge AI, identifying new treatments, de-risking and accelerating clinical trials, and building diagnostic tools to reduce time to impact for patients. The company works with top academic centers to curate, enrich, and generate deep, multimodal data that is AI-ready. Owkin's approach involves applying AI to this data to subtype patients and identify novel biomarkers, informing drug discovery, clinical trial optimization, and diagnostic development. Their platform leverages a federated research network and innovative technologies like MOSAIC to access world-class patient data while maintaining privacy. Owkin's AI capabilities include interpretable predictive models, multiscale AI connecting cellular, molecular, and tissue scales, and state-of-the-art technologies like large language models and foundation models. The company is differentiated by its focus on improving fundamental understanding of disease mechanics through data, biology, and AI, with a lab-in-the-loop approach that integrates wet lab data and AI to accelerate R&D. Owkin's offerings span from AI-powered drug discovery and development to AI diagnostics for digital pathology, including tools like MSIntuit® CRC, RlapsRisk® BC, and TLS-Detect CDx.